QTTB · Annual Report (Form 10-K) · Filed March 10, 2026

Q32 Bio Inc — 10-K exhibit

qttb-ex23_1.htm

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-1 No. 333-278829) of Q32 Bio Inc., as amended by Post-Effective Amendment No. 1 to Form S-1 on Form S-3 Registration Statement (No. 333-278829),

(2)

Registration Statement (Form S-3 No. 333-286491) of Q32 Bio Inc.,

(3)

Registration Statement (Form S-8 No. 333-285699) pertaining to Q32 Bio Inc. 2024 Stock Option and Incentive Plan and Q32 Bio Inc. 2024 Employee Stock Purchase Plan,

(4)

Registration Statement (Form S-8 No. 333-279877) pertaining to Q32 Bio Inc. 2017 Stock Option and Grant Plan, Q32 Bio Inc. 2024 Stock Option and Incentive Plan, Q32 Bio Inc. 2024 Employee Stock Purchase Plan,

(5)

Registration Statement (Form S-8 No. 333-270398) pertaining to the Homology Medicines, Inc. 2018 Incentive Award Plan and Homology Medicines, Inc. 2018 Employee Stock Purchase Plan, and

(6)

Registration Statement (Form S-8 No. 333-224030) pertaining to the Homology Medicines, Inc. 2015 Stock Incentive Plan, as amended, Homology Medicines, Inc. 2018 Incentive Award Plan and Homology Medicines, Inc. 2018 Employee Stock Purchase Plan;

of our report dated March 10, 2026, with respect to the consolidated financial statements of Q32 Bio Inc. included in this Annual Report (Form 10-K) of Q32 Bio Inc. for the year ended December 31, 2025.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 10, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer